CAR-T Immunotherapy is a treatment which optimizes the body’s ability to target, attack and kill tumor cells. On August 30, 2017, the Federal Drug Administration (FDA) approved the Novartis version of CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (ALL), which is the most common form of childhood cancer in America. While current chemotherapy, radiation and bone marrow transplants result in remission for about 80 percent of people with ALL, there are still about 20 percent who do not respond to current treatment. These individuals are said to be refractory to treatment.For them, CAR-T is a lifesaving option. However, medical miracles come at a large cost to health plans and Payors.
Like the war general, the best benefits brokers know that implementing a good benefits plan (or war plan) requires a mixture of science, art, technology and even psychology. When it comes to preempting costly diseases and health plan pitfalls, anticipation and an outside-of-the-box mentality is everything. To have a comprehensive understanding on how individuals function and behave within the health plan design is to be a step ahead of the curve.